



Supplementary figure 1
Gating of cells in ICS analyses.




Supplementary Figure 2

Pulse-chase analysis. Cells were infected with VREP.HIVconsv, pulsed with ^{35}S -methionine and subsequently incubated with unlabeled medium for different times, as indicated. Total cell lysates were normalized for total protein content and loaded onto the gel.





Supplementary figure 3

CD8⁺ T cell responses following a homologous boost with DREP.HIVconsv. Mice were immunized i.d. with EP with 2.5 μg DREP.HIVconsv. 9 weeks later, a homologous boost was administered in the same way. Spleens were collected and analyzed 10 days post-prime or 10, 11 or 12 days post-boost. HIVconsv-specific CD8⁺ T cell responses were assessed with IFN-γ ELISpot. Each group consisted of five mice. Results are displayed as group medians.




Supplementary figure 4

CD8+ T cell responses following MVA.HIVconsv boost. See figure text for figure 4 for technical details. Results are displayed as group medians.




Supplementary figure 5

CD8+ T cell responses following ChAdV63.HIVconsv boost. See figure text for figure 4 for technical details. Results are displayed as group medians.



Supplementary figure 6

CD8+ T cell responses following heterologous prime-boost. See figure text for figure 5 for technical details. Results are displayed as group medians.



Supplementary figure 7

Influence of type I IFNs following immunization of DREP-OVA with skin EP. SV129 or *ifn-ar1*^{-/-} (SV129 background) mice were injected with DREP-OVA or ΔREP-OVA i.d. followed by EP. ΔREP-OVA was created by deleting the replicase genes in DREP-OVA (Näslund *et al.* 2011. *Virology* 438:36). Splensens were collected 10 days later. OVA-specific CD8⁺ T cells were assessed with IFN-γ ELISpot by stimulating with the SIINFEKL peptide (Proimmune). Molarly equivalent doses DREP-OVA and ΔREP-OVA are grouped in the graph. Responses are shown as group medians.